Novel Colon Cancer Treatment Discovered Through Drug Repurposing

Strategic Insights -

Researchers from Shanghai Jiao Tong University School of Medicine in Shanghai, People's Republic of China, have identified a new potential treatment for colon cancer through the repurposing of an existing FDA-approved drug. The study, published in Pharmaceuticals, found that menadione, a small molecular compound, can induce programmed cell death in colorectal cancer cells. This discovery provides a promising alternative to traditional chemotherapy and offers a more efficient approach to discovering new therapies.

Key Takeaways:

  • The researchers screened 1068 small molecular compounds from an FDA-approved drug library and identified menadione as a potent anti-tumor drug.
  • Menadione induced three programmed cell death signaling pathways: necroptosis, apoptosis, and autophagy in colorectal cancer cells.
  • The anti-tumor effect of menadione was mediated through the key gene MAPK8.
  • The study used a combination of cell biology, molecular biology, and bioinformatics to identify menadione as a potential new therapy for colon cancer.
  • The researchers propose that repurposing menadione could provide a faster and more cost-effective approach to developing new treatments for colon cancer.
  • The study's findings have significant implications for the treatment of colon cancer, which is a prevalent gastrointestinal malignancy and the second leading cause of cancer-related mortality worldwide.

Statistics:

  • 1068 small molecular compounds were screened from an FDA-approved drug library.
  • 3 programmed cell death signaling pathways were induced by menadione in colorectal cancer cells.
  • 1 key gene, MAPK8, was found to mediate the anti-tumor effect of menadione.
  • Colon cancer is the second leading cause of cancer-related mortality worldwide.
  • Menadione was identified as a potent anti-tumor drug through a combination of cell biology, molecular biology, and bioinformatics.

Sources:

  • Cao, et al. (2025). Screening of an FDA-Approved Drug Library: Menadione Induces Multiple Forms of Programmed Cell Death in Colorectal Cancer Cells via MAPK8 Cascades. Pharmaceuticals, 18(8), 1145.
  • Gastroenterology Week. (2025, September 8). Reports from Shanghai Jiao Tong University School of Medicine Add New Study Findings to Research in Colon Cancer. Gastroenterology Week, 478.